Founded in part by RiverVest, Lutonix developed the first FDA-approved drug-coated angioplasty balloon catheter that delivers paclitaxel to the arterial wall when used for the treatment of peripheral artery disease. Paclitaxel is an anti-proliferative drug commonly used to prevent restenosis, or re-narrowing of treated arteries post-treatment.

Acquired by C.R. Bard in December 2011.